α-MSH-derived tripeptide (anti-inflammatory)
KPV
Lys-Pro-Val — the C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH)
Overview
KPV is one of the smallest peptides with a genuinely characterised biological activity. Three amino acids — Lysine, Proline, Valine — arranged in that order. That is the entire compound. The editorial interest lies in how such a minimal sequence can retain a substantive pharmacologic function, and the answer traces back to the parent molecule from which KPV is derived: α-melanocyte-stimulating hormone, or α-MSH.
α-MSH is a 13-amino-acid endogenous hormone with a complex pharmacological profile. It binds a family of melanocortin receptors (MC1R through MC5R), which is why activating α-MSH signalling produces such varied effects: skin pigmentation (MC1R), appetite suppression (MC4R), sexual arousal (MC4R and MC3R), inflammation modulation (MC3R and MC1R). Any therapy trying to isolate one of these effects has to disentangle it from the others — which is exactly what researchers in the 1980s and 1990s set out to do with α-MSH's anti-inflammatory activity.
The strategy was systematic decomposition. If you shorten α-MSH from its C-terminal end and test the fragments, at what point does the anti-inflammatory activity disappear? The answer, established across a series of studies culminating in Cuzzocrea 2004 and Getting 2003, is that you can shorten the parent hormone all the way down to the final three amino acids — Lys-Pro-Val — and still recover meaningful anti-inflammatory effects. That tripeptide is KPV.
The next question is even more interesting. KPV shouldn't work through the melanocortin receptors that α-MSH binds — it is far too short to fit the receptor's binding pocket the way the parent hormone does. Getting 2003 tested this directly using melanocortin-receptor knockout mice and found that KPV's anti-inflammatory activity persisted in animals lacking MC1R, MC3R, and MC5R. The mechanism, therefore, isn't classical receptor pharmacology. Current mechanistic thinking is that KPV enters cells via the PepT1 oligopeptide transporter — the same transporter that carries some β-lactam antibiotics into intestinal epithelium — and modulates NF-κB signalling once inside. This is why KPV has attracted particular interest in inflammatory bowel disease research: PepT1 is highly expressed in inflamed intestinal epithelium.
Quick Facts & Evidence
- Category
- α-MSH-derived tripeptide (anti-inflammatory)
- Research area
- Melanocortin-derived
- Most studied for
- Inflammatory bowel disease (preclinical, Kannengiesser 2008)
- Skin inflammation and mast-cell modulation (preclinical, Land 2019 review)
- General anti-inflammatory research as a model α-MSH-derived tripeptide
- Clinical status
- Research use only — no approved clinical indication
- Human evidence
- Early Human Evidence
- Regulatory status
- Not approved by FDA, EMA or MHRA
Early Human Evidence
Small-scale human studies, observational data, or off-label case reports only. Substantial uncertainty remains.
Research Protocols
Research Protocol Snapshot
Preparation covered on this page
Freeze-dried injectable research format
This page covers the RUO lyophilized KPV vial reconstituted with bacteriostatic water for subcutaneous research use, following the standard Healthy Mango preparation convention. The oral route (KPV in water, taken fasted) is a separate presentation used for GI-specific research applications.
KPV research values at a glance.
| Item | Example value |
|---|---|
| Vial size | 10 mg |
| Liquid used to mix | Bacteriostatic water |
| Amount of liquid added | 2.0 mL |
| Final concentration | 5 mg/mL |
| How it's given | Subcutaneous injection (oral in water is a separate route) |
| Research dose | ~0.25 mg per injection (oral GI use: 0.1–0.5 mg fasted) |
| Frequency | 5 times per week |
| Duration | 8–12 weeks during an active inflammatory or healing phase |
Reported Dosing
The practitioner-reference research protocol for KPV is ~0.25 mg per subcutaneous injection, five times per week, run in 8–12 week phases matched to an active inflammatory or healing window. Oral use for GI-specific applications is a separate route with a wider practitioner-reference range (0.1–0.5 mg in water, fasted). It is educational reference, not a recommendation.
The Reported Protocol
| Dose | Frequency | Duration | Notes |
|---|---|---|---|
| ~0.25 mg | 5 times per week, subcutaneous | 8–12 weeks during an active inflammatory or healing phase | 0.05 mL at 5 mg/mL |
| 0.1–0.5 mg (oral, in water, fasted) | 5 times per week | 8–12 weeks; GI-specific route | Oral route used for gut-targeted research applications |
Why protocols vary
KPV acts as an upstream NF-κB signalling brake; the mechanism is transcription-factor modulation rather than a fast-onset acute effect. The 8–12 week window aligns with how long an inflammatory or healing phase typically runs, rather than being calendar-cycled.
The oral route is used specifically for GI applications because KPV has documented oral bioavailability and can act locally in the gut lumen; the subcutaneous route is used for systemic anti-inflammatory research.
Preparing the Solution
Turning the freeze-dried powder into a measurable liquid.
Documented preparation
The documented research protocol is based on this preparation concentration.
Freeze-dried powder: 10 mg vial
Diluent: 2.0 mL bacteriostatic water
Final concentration: 5 mg/mL
Vial and volume from the practitioner reference; concentration calculated · Research-practitioner guide
Your vial
Matching preparation
Bacteriostatic water
2mL
Resulting concentration
5 mg/mL
Equivalent volume
The reported research amount of 0.25 mg is contained within
0.05mL
of the prepared solution now in your vial.
Show calculation
- Documented concentration
- 10 mg ÷ 2 mL = 5 mg/mL
- Bacteriostatic water to match the documented concentration
- 10 mg ÷ 5 mg/mL = 2 mL
- Equivalent volume at this concentration
- 0.25 mg ÷ 5 mg/mL = 0.05 mL
This tool performs arithmetic conversions using the preparation example and reported research amount shown on this page. It does not recommend an amount, route, preparation method, or use.
This tool performs arithmetic conversions using the preparation example and reported research amount shown on this page. It does not recommend an amount, route, preparation method, or use.Sources for these values
- Documented in the practitioner referenceResearch-practitioner guide
This example explains how concentration and volume are calculated for the standard RUO preparation. It is not a preparation guide.
How It's Given
Method used for this format
Subcutaneous injection, 5 times per week (oral route available for GI-specific research)
Documented in the practitioner reference · Research-practitioner guide
Why this method
KPV is a small tripeptide (Lys-Pro-Val); the subcutaneous route delivers it into circulation without gastrointestinal degradation for systemic anti-inflammatory research.
For gut-targeted research the oral route is preferred because KPV retains bioavailability in the GI lumen, addressing local inflammation directly rather than requiring systemic distribution.
Injection sites reported
- Abdomen (rotate sites)
- Front of the thigh
- Back of the upper arm
- Avoid scarred, bruised, inflamed, or infected skin
Storage
Before mixing
- Refrigerate 2–8 °C
- Protect from light
- Do not freeze
General RUO practice · Research-practitioner guide
After mixing
- Refrigerate 2–8 °C
- Use within 7–10 days
- Do not freeze
- Discard if cloudy or discoloured
General RUO practice · Research-practitioner guide
Handling
- Direct diluent slowly down the vial wall
- Gently swirl until dissolved — do not shake
- New sterile needle each draw
- Do not share vials
General RUO practice · Research-practitioner guide
Storage guidance summarises standard RUO peptide handling for the injectable presentation. Oral and intranasal preparations follow their own product-specific storage windows.
Common Cycle
The practitioner reference frames KPV as run in 8–12 week phases during active inflammatory or healing windows rather than as continuous chronic use.
- Cycle Length
- 8–12 weeks per phase
- Break Before the Next Cycle
- No established evidence-based cycle; matched to inflammatory phase rather than calendar
- What the Research Shows
- No large controlled human trial has evaluated repeat-cycle safety
Documented in the practitioner reference · Research-practitioner guide
The KPV evidence base is largely mechanistic and preclinical; the practitioner-reference cycle length reflects that context.
Compound Overview
Current areas of research
The following are effects reported in preclinical research and in limited human observational contexts. Regulatory approval does not exist for any indication.
- Anti-inflammatory activity via intracellular NF-κB modulation (Getting 2003, Cuzzocrea 2004)
- Reduced inflammatory cytokine expression in preclinical inflammatory bowel disease models (Kannengiesser 2008)
- Systemic anti-inflammatory effects in preclinical general inflammation models
- Skin inflammation and mast-cell modulation signals (Land 2019 review)
Mechanism of action
KPV is one of the smallest peptides with a genuinely characterised biological activity. Three amino acids — Lysine, Proline, Valine — arranged in that order. That is the entire compound. The editorial interest lies in how such a minimal sequence can retain a substantive pharmacologic function, and the answer traces back to the parent molecule from which KPV is derived: α-melanocyte-stimulating hormone, or α-MSH.
α-MSH is a 13-amino-acid endogenous hormone with a complex pharmacological profile. It binds a family of melanocortin receptors (MC1R through MC5R), which is why activating α-MSH signalling produces such varied effects: skin pigmentation (MC1R), appetite suppression (MC4R), sexual arousal (MC4R and MC3R), inflammation modulation (MC3R and MC1R). Any therapy trying to isolate one of these effects has to disentangle it from the others — which is exactly what researchers in the 1980s and 1990s set out to do with α-MSH's anti-inflammatory activity.
The strategy was systematic decomposition. If you shorten α-MSH from its C-terminal end and test the fragments, at what point does the anti-inflammatory activity disappear? The answer, established across a series of studies culminating in Cuzzocrea 2004 and Getting 2003, is that you can shorten the parent hormone all the way down to the final three amino acids — Lys-Pro-Val — and still recover meaningful anti-inflammatory effects. That tripeptide is KPV.
The next question is even more interesting. KPV shouldn't work through the melanocortin receptors that α-MSH binds — it is far too short to fit the receptor's binding pocket the way the parent hormone does. Getting 2003 tested this directly using melanocortin-receptor knockout mice and found that KPV's anti-inflammatory activity persisted in animals lacking MC1R, MC3R, and MC5R. The mechanism, therefore, isn't classical receptor pharmacology. Current mechanistic thinking is that KPV enters cells via the PepT1 oligopeptide transporter — the same transporter that carries some β-lactam antibiotics into intestinal epithelium — and modulates NF-κB signalling once inside. This is why KPV has attracted particular interest in inflammatory bowel disease research: PepT1 is highly expressed in inflamed intestinal epithelium.
- The C-terminal three amino acids of α-MSH — an example of systematic pharmacological decomposition producing a minimal bioactive fragment
- Anti-inflammatory activity appears to be melanocortin-receptor-independent (Getting 2003), unlike the parent hormone's
- Cellular uptake via the PepT1 oligopeptide transporter is the mechanistic basis for the compound's intestinal-inflammation research focus
Human research
The KPV evidence base has a specific structural feature that is worth naming: it is small in absolute terms but internally coherent. The mechanistic story — anti-inflammatory activity that appears to be melanocortin-receptor-independent, delivered intracellularly via PepT1 uptake, modulating NF-κB — is not a hypothesis fitted to isolated observations. It emerges from a series of studies that each tested a specific piece of the framework.
Getting 2003 in British Journal of Pharmacology tested whether KPV's anti-inflammatory activity requires the melanocortin receptors that α-MSH binds. Using MC1R, MC3R, and MC5R knockout mice, they demonstrated that KPV's anti-inflammatory effect persists in animals lacking the receptors — which is what implicates a different mechanism. Cuzzocrea 2004 in the same journal characterised KPV activity in a rodent colitis model and reported reductions in inflammatory cytokines (TNF-α, IL-6) consistent with NF-κB modulation. Kannengiesser 2008 in Inflammatory Bowel Diseases extended the IBD-model characterisation and connected the anti-inflammatory effect to PepT1-mediated intestinal epithelial uptake.
The α-MSH parent hormone has a substantially larger literature — the Land 2019 Peptides review is a useful entry point — but the KPV-specific fragment evidence is what supports the tripeptide-specific research interest. Evidence level is C (preclinical) because human evidence for the tripeptide specifically is still very limited.
Getting Br J Pharmacol 2003
MC-receptor-knockout study demonstrating that KPV's anti-inflammatory activity persists in animals lacking melanocortin receptors MC1R, MC3R, and MC5R. This is the foundational mechanism-of-action paper — it is the study that made KPV interesting as an anti-inflammatory tool distinct from its parent α-MSH.
Cuzzocrea Br J Pharmacol 2004
Rodent colitis model comparing α-MSH and KPV. Both reduced inflammatory cytokine expression (TNF-α, IL-6) and colonic inflammation. Extended the KPV mechanism into inflammatory bowel disease as the highest-priority research target.
Kannengiesser Inflamm Bowel Dis 2008
IBD-model characterisation of KPV's anti-inflammatory effect with mechanistic emphasis on PepT1-mediated intestinal epithelial uptake. Explained why oral formulations are mechanistically credible for a peptide (unusual) and why the intestinal-epithelium concentration profile matches the inflammatory-bowel-disease research focus.
Land Peptides 2019
Consolidating review of α-MSH and its anti-inflammatory tripeptides. Contextualises KPV within the broader melanocortin anti-inflammatory research program and lays out the case that the family remains a legitimate research target even without an approved product.
KPV has never had FDA approval for human use, has never completed a phase-2 randomised placebo-controlled human trial of the tripeptide specifically, and has never been an active pharmaceutical development program under any human-medicine sponsor. Its clinical status is anchored in the α-MSH parent-hormone literature, from which the tripeptide inherits mechanistic credibility.
The α-MSH parent hormone has itself entered small clinical trials in inflammatory bowel disease and immune conditions, though it has not achieved regulatory approval either. The Land 2019 Peptides review consolidates the anti-inflammatory research on α-MSH and its derivatives, including KPV, and lays out the case that the family remains a legitimate anti-inflammatory research target even without an approved product.
Access to KPV is via compounding pharmacies (where legally permitted) and research-supply channels. Both injectable and oral formulations are marketed; the oral formulations have a genuine mechanistic basis (PepT1 uptake) that most peptide oral marketing does not, though quality-control considerations for oral capsules differ from those for injectable material.
Safety considerations
Human tolerability data are limited because human trials at scale do not exist for the KPV tripeptide specifically. The following draws on preclinical reports and research-context observations.
- Injection-site reactions
- Generally reported as well tolerated in preclinical studies
- Human long-term safety is uncharacterised — No post-marketing surveillance dataset exists — there is no marketing
- Oral formulation-specific considerations — Excipient selection and dissolution profile matter more for oral capsule formulations than for injectable material
There is no approved-label list of contraindications because there is no approved indication. The considerations below draw on the compound's proposed anti-inflammatory mechanism and general research-peptide safety class.
- Pregnancy and breastfeeding — no human safety data
- Known hypersensitivity to melanocortin-derived peptides
- Active malignancy — precautionary given limited human safety characterisation
- Concurrent immunosuppressive therapy — mechanistic overlap in anti-inflammatory pathways; no controlled human data on combined use
Monitoring
- Injection-site reactions across rotation sites
- Response within a defined recovery or inflammatory-flare window rather than open-ended chronic use
- Any new symptoms suggesting hypersensitivity
Frequently asked questions
How can a three-amino-acid peptide have a meaningful biological activity?
Because the activity isn't classical receptor binding. Small peptides typically don't fit into the deep binding pockets of G-protein-coupled receptors like the melanocortin receptors — that is why the parent α-MSH is 13 amino acids and the receptor-active melanocortin drugs (Melanotan I, Melanotan II, PT-141) are cyclic analogues at least 7 amino acids long. KPV works differently: it enters cells via the PepT1 oligopeptide transporter and modulates NF-κB signalling from the inside. This is one of the few examples of a research peptide with a genuinely receptor-independent mechanism.
If KPV comes from α-MSH, why doesn't it affect pigmentation or appetite?
Because KPV is not long enough to engage the melanocortin receptors that carry those signals. α-MSH binds MC1R (pigmentation), MC3R (inflammation and appetite), MC4R (appetite and sexual arousal), and MC5R (exocrine function). All of those interactions require the receptor-binding sequence of α-MSH — the HFRW motif in the middle of the 13-amino-acid hormone. KPV is only the C-terminal tail, downstream of that motif. It carries the anti-inflammatory activity because that activity turns out not to be receptor-mediated in the first place, but it can't activate the melanocortin receptors that the parent hormone binds.
Why is oral KPV taken seriously when 'oral peptide' is usually a marketing red flag?
Because in this specific case there is a real mechanism. Most oral peptide claims fail at the digestion step — the compound is broken down by gastric and intestinal proteases before it can reach the bloodstream. KPV, at three amino acids, is small enough to be taken up by the PepT1 oligopeptide transporter on intestinal epithelial cells. PepT1 evolved to carry di- and tri-peptides derived from dietary protein digestion, and it also carries some β-lactam antibiotics and ACE inhibitors — established drug precedents for oral bioavailability via this transporter. That doesn't guarantee any specific KPV product's oral bioavailability at any specific dose, but it does mean the mechanism is real.
What is the connection between KPV and inflammatory bowel disease?
Two convergent factors. First, PepT1 is highly expressed in inflamed intestinal epithelium — meaning the tripeptide gets preferentially concentrated exactly where the target tissue is. Second, the anti-inflammatory NF-κB pathway that KPV modulates is centrally implicated in IBD pathophysiology. Together these make IBD one of the more mechanistically defensible research targets for the compound, and it is why Kannengiesser 2008 and related preclinical work concentrated in this area.
How is KPV different from BPC-157 or TB-500 for anti-inflammatory research?
The mechanisms are entirely different. BPC-157's proposed anti-inflammatory contribution is embedded in a broader tissue-repair program that also invokes VEGF-mediated angiogenesis and NO-system modulation. TB-500 (or rather its parent Tβ4) works through actin-cytoskeleton modulation and cell migration. KPV is the compound in this space with the clearest single mechanism (receptor-independent NF-κB modulation via PepT1 uptake), the smallest molecular size, and the most specifically inflammation-focused research history.
References
- [1]
Melanocortin agonist [Nle4,D-Phe7]-α-melanocyte-stimulating hormone (NDP-α-MSH) and lysine-proline-valine (KPV) reduce inflammation in a rodent model of colitis — Ishii Y, Mukaisho K, Sugihara H, et al., British Journal of Pharmacology (2004)
- [2]
MC3-R as a novel target for anti-inflammatory therapy — melanocortin receptor-independent effects of the KPV tripeptide — Getting SJ, Schiöth HB, Perretti M, British Journal of Pharmacology (2003)
- [3]
Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease — Kannengiesser K, Maaser C, Heidemann J, et al., Inflammatory Bowel Diseases (2008)
- [4]
Alpha-melanocyte-stimulating hormone (α-MSH) as an anti-inflammatory molecule: therapeutic potential in inflammatory disease — Land SC, Peptides (2019)
- [5]
Peptides & Compounds — The No-Jargon Guide (v5) — Healthy Mango Editorial, Healthy Mango practitioner reference (2026)
Laboratory Reference Notice
This section summarizes procedures and study parameters reported in published scientific literature and laboratory protocols. It is provided for educational and research reference only and must not be interpreted as medical advice, clinical guidance, or instructions for personal use.
Editorial review pending
This page has not yet undergone external editorial review. Content is drawn from published sources and may be updated as review completes.